216 related articles for article (PubMed ID: 15253477)
21. Renin-angiotensin system blockade is not associated with hyperkalemia in chronic hemodialysis patients.
Lin HH; Yang YF; Chang JK; Ting IW; Kuo HL; Wang IK; Huang CC
Ren Fail; 2009; 31(10):942-5. PubMed ID: 20030530
[TBL] [Abstract][Full Text] [Related]
22. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
Hirai T; Yamaga R; Fujita A; Itoh T
J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
[TBL] [Abstract][Full Text] [Related]
23. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
Agarwal R; Siva S; Dunn SR; Sharma K
Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
Walser M
N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873778
[No Abstract] [Full Text] [Related]
25. Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting.
Kurnik D; Vesterman-Landes J; Bialik M; Katzir I; Lomnicky Y; Halkin H; Loebstein R
Clin Ther; 2011 Apr; 33(4):456-64. PubMed ID: 21635991
[TBL] [Abstract][Full Text] [Related]
26. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
[TBL] [Abstract][Full Text] [Related]
27. Angioedema associated with angiotensin II receptor antagonists: challenging our knowledge of angioedema and its etiology.
Chiu AG; Krowiak EJ; Deeb ZE
Laryngoscope; 2001 Oct; 111(10):1729-31. PubMed ID: 11801934
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome.
Kosmadakis G; Filiopoulos V; Georgoulias C; Tentolouris N; Michail S
Scand J Urol Nephrol; 2010 Sep; 44(4):251-6. PubMed ID: 20201749
[TBL] [Abstract][Full Text] [Related]
29. [Prospective observational study of angiotensin converting enzyme inhibitors-induced hyperkalemia in hospitalized patients with chronic renal failure].
Ben Mahmoud L; Ghozzi H; Kammoun K; Hakim A; Kharrat M; Ben Hmida M; Jarraya F; Sahnoun Z; Zeghal K; Hachicha J
Nephrol Ther; 2013 Apr; 9(2):98-102. PubMed ID: 23022289
[TBL] [Abstract][Full Text] [Related]
30. Hyperkalemia of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in hemodialysis: a meta-analysis.
Zhang Q; Luan H; Wang L; Zhang M; Chen Y; Lv Y; Ma Z
J Huazhong Univ Sci Technolog Med Sci; 2012 Oct; 32(5):785-792. PubMed ID: 23073814
[TBL] [Abstract][Full Text] [Related]
31. Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group.
Lacourcière Y; Brunner H; Irwin R; Karlberg BE; Ramsay LE; Snavely DB; Dobbins TW; Faison EP; Nelson EB
J Hypertens; 1994 Dec; 12(12):1387-93. PubMed ID: 7706699
[TBL] [Abstract][Full Text] [Related]
32. Cough and angiotensin II receptor antagonists: cause or confounding?
Mackay FJ; Pearce GL; Mann RD
Br J Clin Pharmacol; 1999 Jan; 47(1):111-4. PubMed ID: 10073748
[TBL] [Abstract][Full Text] [Related]
33. Low-dose angiotensin II receptor antagonists and angiotensin II-converting enzyme inhibitors alone or in combination for treatment of primary glomerulonephritis.
Renke M; Tylicki L; Rutkowski P; Rutkowski B
Scand J Urol Nephrol; 2004; 38(5):427-33. PubMed ID: 15764256
[TBL] [Abstract][Full Text] [Related]
34. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ
Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666
[TBL] [Abstract][Full Text] [Related]
35. Dual therapy difficulties in angiotensin blockade for proteinuria: a teachable moment.
Hung KW; Blaine J; Faubel S
JAMA Intern Med; 2014 Sep; 174(9):1429-30. PubMed ID: 25089763
[No Abstract] [Full Text] [Related]
36. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
Raebel MA; McClure DL; Simon SR; Chan KA; Feldstein A; Andrade SE; Lafata JE; Roblin D; Davis RL; Gunter MJ; Platt R
Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):55-64. PubMed ID: 16470693
[TBL] [Abstract][Full Text] [Related]
37. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
[TBL] [Abstract][Full Text] [Related]
38. No association of angiotensin-converting enzyme inhibitor or angiotensin 2 receptor blocker intake with acute kidney injury in patients undergoing kidney biopsy.
Friedl A; Peric S; Masghati S; Wolzt M; Hörl WH; Soleiman A; Fuhrmann V; Haider DG
Kidney Blood Press Res; 2012; 35(6):558-60. PubMed ID: 22890200
[TBL] [Abstract][Full Text] [Related]
39. Anaemia due to ACE inhibitors and losartan in patients with renal failure.
Prescrire Int; 1999 Dec; 8(44):179-80. PubMed ID: 11503817
[TBL] [Abstract][Full Text] [Related]
40. Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker.
Jun HR; Kim H; Lee SH; Cho JH; Lee H; Yim HW; Yoon KH; Kim HS
Cardiovasc Ther; 2021; 2021():5935149. PubMed ID: 33747123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
